`
`
`
`
`Paper No. ___
`Filed: May 31, 2018
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`
`MODERNA THERAPEAUTICS, INC.,
`Petitioner,
`
`v.
`
`PROTIVA BIOTHERAPEAUTICS, INC.,
`Patent Owner.
`
`_____________________________
`
`Case IPR2018-00739
`Patent 9,364,435
`_____________________________
`
`PATENT OWNER’S MOTION FOR PRO HAC VICE ADMISSION UNDER
`37 C.F.R. § 42.10(c)
`
`
`
`
`
`
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`I.
`
`STATEMENT OF THE PRECISE RELIEF REQUESTED
`
`Pursuant to the Board’s March 14, 2018 Notice of Filing Date Accorded to
`
`Petition and Time for Filing Patent Owner Preliminary Response (Paper No. 5) and
`
`37 C.F.R. § 42.10(c), Patent Owner Protiva Biotherapeautics, Inc. (“Protiva”)
`
`respectfully requests that the Board recognize Edward Reines of Weil, Gotshal &
`
`Manges LLP as counsel pro hac vice in this proceeding.
`
`Protiva has conferred with Petitioner Moderna Therapeutics, Inc.
`
`(“Moderna”) who has stated it does not oppose this motion.
`
`II. REASONS THE REQUESTED RELIEF SHOULD BE GRANTED
`
`As set forth below in the Statement of Material Facts, Protiva has made all
`
`of the showings required under 37 C.F.R. § 42.10(c) for recognizing Mr. Reines
`
`pro hac vice. In particular, Mr. Reines is an experienced litigating attorney who
`
`has represented clients in numerous patent litigation cases in various United States
`
`District Courts and the Court of Appeals for the Federal Circuit, including
`
`technically and legally complex matters such as will be present in this proceeding.
`
`Mr. Reines has previously appeared pro hac vice in IPR proceedings related to
`
`biotechnology patents, which are at issue here. See, e.g., Ariosa Diagnostics, Inc. v.
`
`Illumina, Inc., IPR2014-01093, Paper No. 29 (March 16, 2015). Accordingly,
`
`allowing Mr. Reines to appear pro hac vice on behalf of Protiva is appropriate in
`
`this proceeding.
`
`
`
`
`
`1
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`III. STATEMENT OF MATERIAL FACTS
`
`1.
`
`37 C.F.R. § 42.10(c) provides that “[t]he Board may recognize
`
`counsel pro hac vice during a proceeding upon a showing of good cause, subject to
`
`the condition that lead counsel be a registered practitioner and to any other
`
`conditions as the Board may impose. For example, where the lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon showing that counsel is an experienced
`
`litigating attorney and has an established familiarity with the subject matter at issue
`
`in the proceeding.”
`
`2.
`
`Lead counsel in this inter partes review proceeding is Michael T.
`
`Rosato. Mr. Rosato is registered to practice before the United States Patent and
`
`Trademark Office and holds Registration No. 52,182.
`
`3.
`
`As set forth in the Declaration of Edward R. Reines (Ex. 2001), Mr.
`
`Reines is an experienced litigating attorney and has an established familiarity with
`
`the subject matter at issue in this proceeding. Ex. 2001, ¶¶ 1-2. In particular, Mr.
`
`Reines has 25 years of experience as a patent litigator and has represented clients
`
`in numerous patent litigation cases in various United States District Courts and the
`
`Court of Appeals for the Federal Circuit. Id. ¶1.
`
`
`
`
`
`
`
`2
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`4.
`
`Further, Mr. Reines is experienced with technically and legally
`
`complex matters in the life sciences, including life sciences-related technologies,
`
`including the following representative matters:
`
`• Verinata Health, Inc. et al. v. Sequenom, Inc. et al. (N.D. Cal.
`
`2012) — Lead trial counsel for Verinata Health in patent litigation
`
`related to prenatal diagnostics based on cell free fetal DNA.
`
`• The Trustees of Columbia University in the City of New York v.
`
`Illumina, Inc. (Fed. Cir. 2014) — Appellate counsel for Illumina in
`
`Federal Circuit appeals of IPR proceedings related to DNA
`
`sequencing nucleotides.
`
`• Promega Corp. v. Life Techs. Corp. et al. (2014) — District court
`
`and appellate counsel for Life Technologies in litigation related to
`
`DNA testing kits.
`
`• Helicos Corp. v. Pacific Biosciences of California, Inc. (D. Del.
`
`2010) — Lead trial counsel for Pacific Biosciences in patent
`
`litigation related to single molecule real time DNA sequencing.
`
`• Applera Corp. and Roche Molecular Sys. v. MJ Research, Inc. (D.
`
`Conn. 2005) — Trial counsel for Applera in six patent litigation
`
`involving foundational PCR intellectual property.
`
`
`
`
`
`
`
`3
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`Id. ¶ 2. Mr. Reines has previously appeared pro hac vice in IPR proceedings
`
`related to biotechnology patents, which are at issue here. See, e.g., Ariosa
`
`Diagnostics, Inc. v. Illumina, Inc., IPR2014-01093, Paper No. 29 (March 16,
`
`2015). Id.
`
`5. Mr. Reines has read and will comply with the Office Patent Trial
`
`Practice Guide and the Board’s Rules of Practice for Trials set forth in Part 42 of
`
`37 C.F.R. Id. ¶ 9. Mr. Reines also agrees to be subject to the United States Patent
`
`and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§
`
`11.101 et seq., and disciplinary jurisdiction under 37 C.F.R. § 11.19(a). Id. ¶10.
`
`6.
`
`Finally, Mr. Reines has attested to the remaining elements of
`
`Admission” in Case IPR2013-00639, Paper 7, Oct. 15, 2013. Id. ¶¶ 3-12; see
`
`Paragraph 2(b) of the representative “Order – Authorizing Motion for Pro Hac Vice
`
`Notice of Filing Date Accorded to Petition and Time for Filing Patent Owner
`
`Preliminary Response (Paper 5) at 2. Regarding the required element in Paragraph
`
`2(b)(iv) of the aforementioned representative order, Mr. Reines in his declaration at
`
`¶ 6 has provided an explanation of the circumstances relating to the Federal Circuit
`
`reprimand of November 5, 2014, as required under Paragraph 2(c) of the
`
`aforementioned representative order. Also submitted with his declaration is the
`
`explanation of circumstances that Mr. Reines submitted to the Federal Circuit.
`
`Exhibit 2003.
`
`
`
`
`
`
`
`4
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`IV.
`
`CONCLUSION
`
`For the foregoing reasons, Protiva respectfully requests that the Board admit
`
`Edward R. Reines of Weil, Gotshal & Manges LLP as counsel Pro Hac Vice in this
`
`proceeding.
`
`
`
`Date: May 31, 2018
`
`
`
`Respectfully submitted,
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`
`Exhibit No
`
`2001
`
`2002
`
`2003
`
`LIST OF EXHIBITS
`
`Description
`
`Declaration of Edward R. Reines in Support of Patent Owner’s
`Motion for Pro Hac Vice Admission
`
`In re Reines, No. 14-MA004 (14-4) (Fed. Cir. Nov. 5, 2014)
`
`Personal Statement of Edward R. Reines
`
`
`
`
`
`
`
`6
`
`
`
`Case IPR2018-00739
`Patent 9,364,435
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that the foregoing Patent Owner’s Motion for Pro Hac Vice
`
`Admission Under 37 C.F.R. § 42.10(c) and Exhibits 2001 through 2003 were
`
`served on this 31st day of May, 2018, on the Petitioner at the electronic service
`
`addresses of the Petitioner as follows:
`
`
`Michael Fleming
`C. Maclain Wells
`Alan Heinrich
`IRELL & MANELLA LLP
`mfleming@irell.com
`mwells@irell.com
`aheinrich@irell.com
`ModernaIPR@irell.com
`
`
`
`
`Date: May 31, 2018
`
`
`
`Respectfully submitted,
`
`
`/ Michael T. Rosato /
`Michael T. Rosato, Lead Counsel
`Reg. No. 52,182
`
`
`
`
`
`
`
`
`
`
`
`
`
`7
`
`